Home › Compound Library › Tenofovir Alafenamide (TAF / Vemlidy)

Tenofovir Alafenamide (TAF / Vemlidy)

Antiretroviralprescriptionoral · inferred

Next-generation tenofovir prodrug optimized to deliver intracellular tenofovir-diphosphate at much lower plasma tenofovir exposure than TDF, substantially reducing renal and bone toxicity. Plasma TAF half-life very short (~0.5h) as it is rapidly taken up into target cells where it is hydrolyzed; intracellular TFV-DP half-life ~150-180h. Used in Descovy, Biktarvy, Genvoya, Odefsey. Oral bioavailability ~40%.

Projected serum levels — 25 mg, once daily

Tenofovir Alafenamide (TAF / Vemlidy)
Tenofovir Alafenamide (TAF / Vemlidy) modeled serum levels, 25 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 1.3 2.5 3.8 5 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 25 mg once daily (oral).

Modeled steady state after ~1 days: peak ≈ 3.7 mg, trough ≈ 0.000 mg body load. Population-based estimate over 15 days for a 25 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Antiretroviral
Route modeled
Oral
Model confidence
inferred
Half-life
30 min
Common dose
25 mg
Suggested maximum
25 mg/day
Reference dose range
12.5–25 mg (single dose)
Suggested cadence
once daily
Validated against
25 mg oral — Cmax 0.20 mg/L at 1 h

Documented interactions

  • moderate
    Apigenin + Tenofovir Alafenamide (TAF / Vemlidy) Transporter inhibition

    Apigenin inhibitor of BCRP may alter Tenofovir Alafenamide (TAF / Vemlidy) absorption / distribution

  • moderate
    Carvedilol (Coreg) + Tenofovir Alafenamide (TAF / Vemlidy) Transporter inhibition

    Carvedilol (Coreg) inhibitor of P-gp may alter Tenofovir Alafenamide (TAF / Vemlidy) absorption / distribution

  • moderate
    CBD (Cannabidiol) + Tenofovir Alafenamide (TAF / Vemlidy) Transporter inhibition

    CBD (Cannabidiol) inhibitor of P-gp may alter Tenofovir Alafenamide (TAF / Vemlidy) absorption / distribution

  • moderate
    Efavirenz (Sustiva) + Tenofovir Alafenamide (TAF / Vemlidy) CYP induction

    Efavirenz (Sustiva) inducer of CYP3A4 predicted to change Tenofovir Alafenamide (TAF / Vemlidy) AUC by ~0.73x

  • moderate
    Fisetin + Tenofovir Alafenamide (TAF / Vemlidy) Transporter inhibition

    Fisetin inhibitor of BCRP may alter Tenofovir Alafenamide (TAF / Vemlidy) absorption / distribution

  • moderate
    Ginkgo Biloba (EGb 761) + Tenofovir Alafenamide (TAF / Vemlidy) Transporter inhibition

    Ginkgo Biloba (EGb 761) inhibitor of P-gp may alter Tenofovir Alafenamide (TAF / Vemlidy) absorption / distribution

Serum checks 30 modeled interaction pairings for tenofovir alafenamide (taf / vemlidy) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection Sax PE et al. · Lancet, 2015 DOI

    Phase 3 non-inferiority trial showing TAF-containing regimen matched TDF efficacy with improved renal and bone safety profile, driving the clinical pivot to TAF.

  2. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults Ruane PJ et al. · Journal of Acquired Immune Deficiency Syndromes, 2013 DOI

    First-in-class monotherapy PK/PD study establishing TAF's dose-response and potent intracellular TFV-DP delivery at low plasma tenofovir exposures.

2 published studies referenced in the app, each with a plain-language summary.